Metropolis Healthcare Share Price
METROPOLIS
Metropolis Healthcare Share Price Chart
About Metropolis Healthcare
Metropolis Healthcare Financials
Market cap ₹10,979 Crs | Open ₹2,134.85 | Close ₹2,141.60 |
Circuit range ₹2,355.75 - ₹1,927.45 | Day range ₹2,128.10 - ₹2,187.65 | Year range ₹1,450.00 - ₹2,318.30 |
Volume 60,141 | Avg. traded ₹2,159.77 | Revenue (12m) ₹1,285 Crs |
Engaged in diagnostic services, Metropolis Healthcare Limited offers a range of clinical laboratory tests and profiles used for early detection, confirmation and monitoring of disease. It also offers analytical and support services to clinical research organisations for their clinical research projects. The company’s services include pathology testing services, corporate wellness, clinical research services and labs in hospitals. Metropolis Healthcare owns diagnostic centres in the Middle East, South Asia and Africa along with its network in India spread across more than 220 cities.
Metropolis has invested in a variety of specialised tests and several advanced tests and technologies introduced in the global market. The company has nearly 2800 specialised tests.
Business operations
Metropolis Healthcare was started in 1980 as a single diagnostic laboratory in Mumbai by Dr Sushil Kanubhai Shah. The company became a public entity in 2006 and was renamed Metropolis Health Services (India) Limited. The company established its first referral laboratory in 1981. Metropolis started clinical research services in 1992. Ameera Sushil Shah joined the team of Metropolis as one of the partners in the company in 1998. She played a major role in the company's growth strategy and was key to its expansion. In 2001, the company completed its first major acquisition and took over the business of Sudharma, Kerala, in 2001. The same year the company introduced its home service vertical.
In 2006, Metropolis received capital funding from ICICI Ventures. The company executed a secondary transaction by Foxcreek Investment Limited, an affiliate company of Warburg Pincus. The company sets its foot outside the Indian market, taking its services to developing African countries. In 2015, Warburg Pincus exited the company, giving the promoters management control of the firm.
The company inducted a new professional team and rolled out the Metropolis retail strategy in 2016.
In 2019-20, was a year of growth for the company as it pushed for retail expansion. Metropolis also initiated its first public-private partnership (PPP). The company launched its initial public offering (IPO) and was listed on the Indian stock markets.
In 2021-22, the company acquired Hitech Diagnostics Centre to boost its presence in the South Indian markets. It also initiated a network expansion project (90:30) with 90 labs and 1,800 service collection centres in tier 2 and tier 3 cities across India. Metropolis absorbed 8 wholly-owned subsidiaries into the company.
It also became the industry’s first firm to introduce an Employee Value Proposition (EVO). The company rolled out the Metropolis 3.0 strategy to expand its consumer reach via a direct-to-consumer model.
As of January 10, 2024, the company’s market capitalisation is valued at over ₹ 8,200 crores. Metropolis Healthcare’s share price has slipped by over 23% in the last three years.
Financial highlights
⦁ Metropolis Healthcare’s total revenue from operations in FY23 stood at ₹1148. 2 crores, recording a dip of 10.86% from ₹1228.34 crores in the last financial year. ⦁ The company reported a net profit of ₹143.4 crore in FY23 as against ₹215 crore in FY22. ⦁ The EBITDA stood at ₹293 crore in FY23, as compared to ₹349 crore in the previous financial year, recording a decline of 16%. ⦁ Its basic earnings per share (EPS) slipped to ₹27.91 in FY23 from ₹41.87 in the last financial year.
Metropolis Healthcare Key indicators
52 week high ₹2,318.30 | 52 week low ₹1,450.00 | P/E ratio 74.44 |
P/B ratio 9.28 | ROE 11.87% | ROCE 18.02% |
Dividend yield 0.19% | Debt/Equity ratio | EPS 22.62 |
Learn more
Sector
Equity returns
Dividend returns
Safety factor
Growth factor
Debt vs Equity
Profit factor
The investment checklist helps you understand a company's financial health at a glance and identify quality investment opportunities easily
Analyst ratings:
Analyst ratings:
56%
Hold
6%
Sell
38%
This analysis is based on the reviews of 16 experts in the last 7 days
Metropolis Healthcare Fundamentals
Metropolis Healthcare Financial Ratios
Operating profit margin24.96% | Net profit margin10.5% |
ROE11.87% | ROA7.32% |
ROCE18.02% |
Quick ratio1.02 | Current ratio1.14 |
Interest coverage6.78 | Asset turnover0.7 |
Debt to Equity0 |
P/E ratio74.44 | P/B ratio9.28 |
EV / EBITDA32 | |
Dividend yield0.19% |
Learn more
Revenue statement
All values are in ₹ Crores (Cr)Learn more
Cash flow
All values are in ₹ Crores (Cr)Learn more
Balance sheet
All values are in ₹ Crores (Cr)Total assets
Total liabilities
Learn more
Metropolis Healthcare Share Price history
Day | Open | Close | Change % |
---|---|---|---|
Fri, Nov 29 2024 | ₹2,130.95 | ₹2,141.60 | |
Thu, Nov 28 2024 | ₹2,175.00 | ₹2,139.85 | -1.30% |
Wed, Nov 27 2024 | ₹2,153.95 | ₹2,168.00 | |
Tue, Nov 26 2024 | ₹2,113.00 | ₹2,157.95 | |
Mon, Nov 25 2024 | ₹2,068.00 | ₹2,118.10 | |
Fri, Nov 22 2024 | ₹2,010.00 | ₹2,061.85 | |
Thu, Nov 21 2024 | ₹2,007.80 | ₹2,015.75 | -0.24% |
Tue, Nov 19 2024 | ₹2,025.70 | ₹2,020.70 | -0.02% |
Events
Corporate actions
Dividend • ₹4/share
Ex date 17 Nov 2023
Dividend • ₹8/share
Ex date 23 Feb 2023
Dividend • ₹8/share
Ex date 21 Feb 2022
Learn more